Safety of hormonal contraception for obese women

References

• World Health Organization. Obesity and overweight. 2016. [cited 2016 Nov 22]. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/
   Google Scholar
• McKeating A, O’Higgins A, Turner C, et al. The relationship between unplanned pregnancy and maternal body mass index 2009-2012. Eur J Contracept Reprod Health Care. 2015;20:409–418.
   PubMed Web of Science ®Google Scholar
• Kulie T, Slattengren A, Redmer J, et al. Obesity and women’s health: an evidence-based review. J Am Board Fam Med. 2011;24:75–85.
   PubMed Web of Science ®Google Scholar
• Stothard KJ, Tennant PW, Bell R, et al. Maternal overweight and obesity and the risk of congenital anomalies: a systematic review and meta-analysis. Jama. 2009;301:636–650.
   PubMed Web of Science ®Google Scholar
• Chu SY, Bachman DJ, Callaghan WM, et al. Association between obesity during pregnancy and increased use of health care. N Engl J Med. 2008;358:1444–1453.
   PubMed Web of Science ®Google Scholar
• Cnattingius S, Bergstrom R, Lipworth L, et al. Prepregnancy weight and the risk of adverse pregnancy outcomes. N Engl J Med. 1998;338:147–152.
   PubMed Web of Science ®Google Scholar
• Chuang CH, Chase GA, Bensyl DM, et al. Contraceptive use by diabetic and obese women. Womens Health Issues. 2005;15:167–173.
   PubMed Web of Science ®Google Scholar
• Schraudenbach A, McFall S. Contraceptive use and contraception type in women by body mass index category. Womens Health Issues. 2009;19:381–389.
   PubMed Web of Science ®Google Scholar
• Bhuva K, Kraschnewski JL, Lehman EB, et al. Does body mass index or weight perception affect contraceptive use? Contraception. 2017;95:59–64.
   PubMed Web of Science ®Google Scholar
• Robinson JA, Burke AE. Obesity and hormonal contraceptive efficacy. Womens Health (Lond). 2013;9:453–466.
   PubMedGoogle Scholar
• Lopez LM, Bernholc A, Chen M, et al. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev. 2016;CD008452.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Guidelines approved by the Guidelines Review Committee. Medical Eligibility Criteria for Contraceptive Use. Geneva: World Health Organization Copyright (c) World Health Organization; 2015.
   Google Scholar
• Allen C, Evans G, Sutton EL. Pharmacologic therapies in women’s health: contraception and menopause treatment. Med Clin North Am. 2016;100:763–789.
   PubMed Web of Science ®Google Scholar
• Lidegaard O, Lokkegaard E, Svendsen AL, et al. Hormonal contraception and risk of venous thromboembolism: national follow-up study. Bmj. 2009;339:b2890.
   PubMed Web of Science ®Google Scholar
• Merki-Feld GS, Skouby S, Serfaty D, et al. European society of contraception statement on contraception in obese women. Eur J Contracept Reprod Health Care. 2015;20:19–28.
   PubMed Web of Science ®Google Scholar
• Rosenberg M. Weight change with oral contraceptive use and during the menstrual cycle. Results of daily measurements. Contraception. 1998;58:345–349.
   PubMed Web of Science ®Google Scholar
• Grimes DA, Schulz KF. Nonspecific side effects of oral contraceptives: nocebo or noise? Contraception. 2011;83:5–9.
   PubMed Web of Science ®Google Scholar
• Coney P, Washenik K, Langley RG, et al. Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception. 2001;63:297–302.
   PubMed Web of Science ®Google Scholar
• Redmond G, Godwin AJ, Olson W, et al. Use of placebo controls in an oral contraceptive trial: methodological issues and adverse event incidence. Contraception. 1999;60:81–85.
   PubMed Web of Science ®Google Scholar
• Gallo MF, Lopez LM, Grimes DA, et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev. 2011;Cd003987.
   PubMed Web of Science ®Google Scholar
• Mohamed AM, El-Sherbiny WS, Mostafa WA. Combined contraceptive ring versus combined oral contraceptive (30-mug ethinylestradiol and 3-mg drospirenone). Int J Gynaecol Obstet. 2011;114:145–148.
   PubMed Web of Science ®Google Scholar
• Bjorkelund C, Lissner L, Andersson S, et al. Reproductive history in relation to relative weight and fat distribution. Int J Obes Relat Metab Disord. 1996;20:213–219.
   PubMed Web of Science ®Google Scholar
• Modesto W, de Nazare Silva Dos Santos P, Correia VM, et al. Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use. Eur J Contracept Reprod Health Care. 2015;20:57–63.
   PubMed Web of Science ®Google Scholar
• Lopez LM, Ramesh S, Chen M, et al. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev. 2016;CD008815.
   PubMed Web of Science ®Google Scholar
• Ray S, Sovani VB. A postmarketing observational study assessing acceptability and reliability of desogestrel only contrapceptive pill (Cerazette) in Indian women. J Indian Med Assoc. 2006;104:653–656.
   PubMedGoogle Scholar
• Xu H, Wade JA, Peipert JF, et al. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. Obstet Gynecol. 2012;120:21–26.
   PubMed Web of Science ®Google Scholar
• Graesslin O, Korver T. The contraceptive efficacy of Implanon: a review of clinical trials and marketing experience. Eur J Contracept Reprod Health Care. 2008;13 Suppl 1:4–12.
   PubMed Web of Science ®Google Scholar
• Vickery Z, Madden T, Zhao Q, et al. Weight change at 12 months in users of three progestin-only contraceptive methods. Contraception. 2013;88:503–508.
   PubMed Web of Science ®Google Scholar
• Pantoja M, Medeiros T, Baccarin MC, et al. Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive. Contraception. 2010;81:107–111.
   PubMed Web of Science ®Google Scholar
• Hassan DF, Petta CA, Aldrighi JM, et al. Weight variation in a cohort of women using copper IUD for contraception. Contraception. 2003;68:27–30.
   PubMed Web of Science ®Google Scholar
• Zuurbier SM, Arnold M, Middeldorp S, et al. Risk of cerebral venous thrombosis in obese women. JAMA Neurol. 2016;73:579–584.
   PubMed Web of Science ®Google Scholar
• Practice Committee of the American Society for Reproductive Medicine. Combined hormonal contraception and the risk of venous thromboembolism: a guideline. Fertil Steril. 2017;107:43–51.
   PubMed Web of Science ®Google Scholar
• Sugiura K, Kobayashi T, Ojima T. Risks of thromboembolism associated with hormonal contraceptives related to body mass index and aging in Japanese women. Thromb Res. 2016;137:11–16.
   PubMed Web of Science ®Google Scholar
• Oelkers W, Helmerhorst FM, Wuttke W, et al. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers. Gynecol Endocrinol. 2000;14:204–213.
   PubMed Web of Science ®Google Scholar
• Lidegaard O, Nielsen LH, Skovlund CW, et al. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. Bmj. 2012;344:e2990.
   PubMed Web of Science ®Google Scholar
• Pomp ER, Le Cessie S, Rosendaal FR, et al. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol. 2007;139:289–296.
   PubMed Web of Science ®Google Scholar
• Mantha S, Karp R, Raghavan V, et al. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ. 2012;345:e4944.
   PubMed Web of Science ®Google Scholar
• Sidney S, Petitti DB, Soff GA, et al. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. Contraception. 2004;70:3–10.
   PubMed Web of Science ®Google Scholar
• Pomp ER, Lenselink AM, Rosendaal FR, et al. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008;6:632–637.
   PubMed Web of Science ®Google Scholar
• Tepper NK, Marchbanks PA, Curtis KM. Superficial venous disease and combined hormonal contraceptives: a systematic review. Contraception. 2016;94:275–279.
   PubMed Web of Science ®Google Scholar
• De Bastos M, Stegeman BH, Rosendaal FR, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014;CD010813.
   PubMed Web of Science ®Google Scholar
• Junge W, Mellinger U, Parke S, et al. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study. Clin Drug Investig. 2011;31:573–584.
   PubMed Web of Science ®Google Scholar
• Goldstein J, Cushman M, Badger GJ, et al. Effect of depomedroxyprogesterone acetate on coagulation parameter: a pilot study. Fertil Steril. 2007;87:1267–1270.
   PubMed Web of Science ®Google Scholar
• Segall-Gutierrez P, Xiang AH, Watanabe RM, et al. Deterioration in cardiometabolic risk markers in obese women during depot medroxyprogesterone acetate use. Contraception. 2012;85:36–41.
   PubMed Web of Science ®Google Scholar
• Dilshad H, Yousuf RI, Shoaib MH, et al. Cardiovascular disease risk associated with the long-term use of depot medroxyprogesterone acetate. Am J Med Sci. 2016;352:487–492.
   PubMed Web of Science ®Google Scholar
• Seeber B, Ziehr SC, Gschliebetaer A, et al. Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system. Contraception. 2012;86:345–349.
   PubMed Web of Science ®Google Scholar
• Zueff LFN, Melo AS, Vieira CS, et al. Cardiovascular risk markers among obese women using the levonorgestrel-releasing intrauterine system: a randomised controlled trial. Obes Res Clin Pract. 2017. DOI: 10.1016/j.orcp.2017.06.001. [Epub ahead of print]
   PubMedGoogle Scholar
• Bahamondes L, Valeria Bahamondes M, Shulman LP. Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods. Hum Reprod Update. 2015;21:640–651.
   PubMed Web of Science ®Google Scholar
• Murthy AS. Obesity and contraception: emerging issues. Semin Reprod Med. 2010;28:156–163.
   PubMed Web of Science ®Google Scholar
• Edelman AB, Carlson NE, Cherala G, et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. Contraception. 2009;80:119–127.
   PubMed Web of Science ®Google Scholar
• Yamazaki M, Dwyer K, Sobhan M, et al. Effect of obesity on the effectiveness of hormonal contraceptives: an individual participant data meta-analysis. Contraception. 2015;92:445–452.
   PubMed Web of Science ®Google Scholar
• McNicholas C, Madden T, Secura G, et al. The Contraceptive CHOICE Project round up: what we did and what we learned. Clin Obstet Gynecol. 2014;57:635–643.
   PubMed Web of Science ®Google Scholar
• McNicholas C, Zhao Q, Secura G, et al. Contraceptive failures in overweight and obese combined hormonal contraceptive users. Obstet Gynecol. 2013;121:585–592.
   PubMed Web of Science ®Google Scholar
• Korver T, Klipping C, Heger-Mahn D, et al. Maintenance of ovulation inhibition with the 75-microg desogestrel-only contraceptive pill (Cerazette) after scheduled 12-h delays in tablet intake. Contraception. 2005;71:8–13.
   PubMed Web of Science ®Google Scholar
• Collaborative Study Group on the Desogestrel-containing Progestogen-only Pill. A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 micrograms/day or levonorgestrel 30 micrograms/day. Collaborative Study Group on the Desogestrel-containing Progestogen-only Pill. Eur J Contracept Reprod Health Care. 1998;3:169–178.
   PubMedGoogle Scholar
• Benagiano G, Primiero FM. Seventy-five microgram desogestrel minipill, a new perspective in estrogen-free contraception. Ann N Y Acad Sci. 2003;997:163–173.
   PubMed Web of Science ®Google Scholar
• Zieman M, Guillebaud J, Weisberg E, et al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril. 2002;77:S13–18.
   PubMed Web of Science ®Google Scholar
• Segall-Gutierrez P, Taylor D, Liu X, et al. Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously. Contraception. 2010;81:487–495.
   PubMed Web of Science ®Google Scholar
• Moraes LG, Marchi NM, Pitoli AC, et al. Assessment of the quality of cervical mucus among users of the levonorgestrel-releasing intrauterine system at different times of use. Eur J Contracept Reprod Health Care. 2016;21:318–322.
   PubMed Web of Science ®Google Scholar
• Birgisson NE, Zhao Q, Secura GM, et al. Preventing unintended pregnancy: the Contraceptive CHOICE Project in review. J Womens Health (Larchmt). 2015;24:349–353.
   PubMed Web of Science ®Google Scholar
• Croxatto HB. Mechanisms that explain the contraceptive action of progestin implants for women. Contraception. 2002;65:21–27.
   PubMed Web of Science ®Google Scholar
• Mornar S, Chan LN, Mistretta S, et al. Pharmacokinetics of the etonogestrel contraceptive implant in obese women. Am J Obstet Gynecol. 2012;207:110.e111-116.
   PubMed Web of Science ®Google Scholar
• Mody SK, Han M. Obesity and contraception. Clin Obstet Gynecol. 2014;57:501–507.
   PubMed Web of Science ®Google Scholar
• Reifsnider E, Mendias N, Davila Y, et al. Contraception and the obese woman. J Am Assoc Nurse Pract. 2013;25:223–233.
   PubMed Web of Science ®Google Scholar
• Ginstman C, Frisk J, Ottosson J, et al. Contraceptive use before and after gastric bypass: a questionnaire study. Obes Surg. 2015;25:2066–2070.
   PubMed Web of Science ®Google Scholar
• Merhi ZO. Impact of bariatric surgery on female reproduction. Fertil Steril. 2009;92:1501–1508.
   PubMed Web of Science ®Google Scholar
• Jatlaoui TC, Cordes S, Goedken P, et al. Family planning knowledge, attitudes and practices among bariatric healthcare providers. Contraception. 2016;93:455–462.
   PubMed Web of Science ®Google Scholar
• Curtis KM, Jamieson DJ, Peterson HB, et al. Adaptation of the World Health Organization’s medical eligibility criteria for contraceptive use for use in the United States. Contraception. 2010;82:3–9.
   PubMed Web of Science ®Google Scholar
• Merhi ZO. Revisiting optimal hormonal contraception following bariatric surgery. Contraception. 2013;87:131–133.
   PubMed Web of Science ®Google Scholar